首页> 外文OA文献 >Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

【2h】

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

机译：含或不含奥沙利铂或伊立替康的氟嘧啶类药物在二期或三年无病生存期（DFS）作为III期辅助结肠癌试验的主要终点：来自MOSAIC，X-ACT，PETACC-3，C- 06，C-07和C89803

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

status: published

机译：状态：已发布

著录项

作者
Sargent, D; Shi, Q; Yothers, G; Van Cutsem, Eric; Cassidy, J; Saltz, L; Wolmark, N; Bot, B; Grothey, A; Buyse, M; de Gramont, A;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献

1. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. [J] . Sargent D, Shi Q, Yothers G, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2011,第7期

机译：含氟嘧啶或不加奥沙利铂或伊立替康的三期辅助结肠癌试验以两年或三年无病生存（DFS）为主要终点：来自MOSAIC，X-ACT，PETACC-3，C- 06，C-07和C89803。
2. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial [J] . Andre Thierry, Vernerey Dewi, Mineur Laurent, Journal of Clinical Oncology . 2018,第15期

机译：三个与6个月的oxaliplatin辅助化疗为III阶段结肠癌患者：无病的生存结果来自随机，开放标签，佐剂国际持续时间评估（想法）法国，第三阶段试验
3. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for PatientsWith Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial (vol 36, pg 1469, 2018) [J] . Andre Journal of Clinical Oncology . 2018,第18期

机译：三个与6个月的oxaliplatin为基于患者的辅助化疗，患者患者III阶段III结肠癌：无病的生存结果来自随机，开放标签，国际持续时间评估的佐剂（想法）法国，III期试验（Vol 36，PG 1469， 2018年）
4. Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12676 patients from MOSAIC X-ACT PETACC-3 C-06 C-07 and C89803 [O] . D Sargent, Q Shi, G Yothers, -1

机译：两个或三个年无病生存（DFs）其为主要终点与具有或不具有奥沙利铂或伊立替康氟尿嘧啶阶段III佐剂结肠癌试验：从mOsaICX-aCTpETaCC-3C-06C数据从12676患者-07和C89803
5. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. [O] . Sargent D, Shi Q, Yothers G, 2011

机译：两年或三年无病生存（DFs）作为III期辅助结肠癌试验的主要终点，氟嘧啶含或不含奥沙利铂或伊立替康：来自mOsaIC，X-aCT，pETaCC-3，C-的12,676名患者的数据06，C-07和C89803。

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

摘要

著录项

相似文献

相关主题

期刊订阅